Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial
Saved in:
| Published in: | Neurology and Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867301677949779972 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Neurology and Therapy |
| description | |
| discipline_display | Psychiatry and Neurology |
| discipline_facet | Psychiatry and Neurology |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:59304 |
| institution | FRELIP |
| journal_source_facet | Neurology and Therapy |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial Psychiatry and Neurology General Psychiatry and Neurology |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Psychiatry and Neurology General Psychiatry and Neurology Psychiatry and Neurology General Psychiatry and Neurology |
| subject_facet | Psychiatry and Neurology General Psychiatry and Neurology |
| title | Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial |
| title_auth | Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial |
| title_full | Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial |
| title_fullStr | Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial |
| title_full_unstemmed | Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial |
| title_short | Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial |
| title_sort | safety and efficacy of obinutuzumab β (mil62), a novel glycoengineered type ii anti-cd20 monoclonal antibody, in patients with neuromyelitis optica spectrum disorder: a multicenter, single-arm, phase ib clinical trial |
| topic | Psychiatry and Neurology General Psychiatry and Neurology |
| url | https://link.springer.com/article/10.1007/s40120-026-00960-w |